✦ LIBER ✦

P-288 Azacitidine therapy in high-risk myelodysplastic syndromes (MDS): A single centre experience

✍ Scribed by Improta, S.; Gagliardi, A.; Villa, M.R.; Cioppa, P. Della; Esposito, M.; Izzo, G. Nitrato; Mastrullo, L.

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

P-120 Risk factors in myelodysplastic sy

✍ Improta, S.; Villa, M.R.; Gagliardi, A.; Cioppa, P. Della; Lucania, A.; Izzo, G. 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 158 KB

P-299 Azacitidine in high-risk MDS patie

✍ Greco, R.; Riva, M.; Ravano, E.; Molteni, A.; Morra, E. 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 67 KB

P-317 Immunosuppressive therapy for pati

✍ Prica, A.; Wells, R.; Buckstein, R.; Chodirker, L. 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 68 KB

Treatment with alpha-lymphoblastoid inte

✍ M.C. Petti; R. Latagliata; M.A. Aloe Spiriti; G. Avvisati; C. DeGregoris; P. Pon 📂 Article 📅 1994 🏛 Elsevier Science 🌐 English ⚖ 142 KB

P-301 Results of 5-azacitidine therapy i

✍ Freyrie, A.; Reda, G.; Vincenti, D.; Ferla, V.; Orofino, N.; Sciumè, M.; Guidott 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 86 KB

161 G-CSF treatment after intensive chem

✍ C. Bernasconi; E.P. Alessandrino; P. Bernasconi; M. Bonfichi; D. Caldera; M. Laz 📂 Article 📅 1997 🏛 Elsevier Science 🌐 English ⚖ 166 KB